ArticleThe Journal of biological chemistry2026
Profiling of fatty acids and lipids in animal and human tissues yields new leads for disease progression biomarkers of X-linked adrenoleukodystrophy.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid signature in X-ALD: a comparison between phenotypes.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X-ALD is a rare disorder caused by impaired β-oxidation of very long-chain fatty acids, their accumulation, and incorporation in lipids, resulting in pathology, severely impacting the central nervous system. Thorough comparative profiling of fatty acids and lipids in different human tissues and biological fluids described in this manuscript has revealed significant differences in composition, which explained why blood lipids successfully used as diagnostics biomarkers for X-ALD do not correlate with disease progression and cannot inform decision-making regarding medical intervention. Our data yielded insights into understanding why the metabolic disorder resulting in elevated levels of VLCFAs in all tissues in X-ALD patients causes severe pathology limited to the central nervous system. We then conducted global lipid profiling of cerebrospinal fluid from pediatric patients and, using data filtering based on disease progression trend, identified new leads for lipid markers with strong disease progression correlations. Data suggests that a few associated proteins should be evaluated as potential biomarkers that may be detectable in blood. We also present data from lipids and fatty acids profiling of tissues from the X-ALD mouse model and WT mice, and comparison with the profiling data obtained for human tissues. This analysis yielded clues to understanding why the ABCD1 KO mouse model, which has the relevant biochemical phenotype, develops only a subtle pathology, while in humans, disease manifestation is severe. In the ABCD1 KO mouse longitudinal study reported in this manuscript, we have identified trending lipids that may serve as sensitive biomarkers of fatty acid metabolism modulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.